Explore the words cloud of the EURE-CART project. It provides you a very rough idea of what is the project "EURE-CART" about.
The following table provides information about the project.
Coordinator |
MOLECULAR MEDICINE SPA
Organization address contact info |
Coordinator Country | Italy [IT] |
Project website | https://www.eure-cart.eu/ |
Total cost | 5˙903˙146 € |
EC max contribution | 5˙903˙146 € (100%) |
Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
Code Call | H2020-SC1-2016-RTD |
Funding Scheme | RIA |
Starting year | 2017 |
Duration (year-month-day) | from 2017-01-01 to 2020-12-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | MOLECULAR MEDICINE SPA | IT (MILANO) | coordinator | 1˙994˙575.00 |
2 | OSPEDALE SAN RAFFAELE SRL | IT (MILANO) | participant | 1˙112˙500.00 |
3 | UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT | DE (WURZBURG) | participant | 856˙076.00 |
4 | OSPEDALE PEDIATRICO BAMBINO GESU | IT (ROMA) | participant | 492˙431.00 |
5 | ACROMION GMBH | DE (FRECHEN) | participant | 398˙000.00 |
6 | ARTTIC | FR (PARIS) | participant | 375˙000.00 |
7 | FUNDACIO PRIVADA INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU | ES (BARCELONA) | participant | 225˙011.00 |
8 | ISTITUTO SUPERIORE DI SANITA | IT (ROMA) | participant | 225˙000.00 |
9 | FAKULTNI NEMOCNICE OSTRAVA | CZ (OSTRAVA PORUBA) | participant | 224˙552.00 |
Cancer is rapidly becoming the most frequent cause of death in EU. Though enormously expensive (several billions EUR/year), currently available anti-cancer therapies are major causes of chronic diseases. Adoptive immunotherapy with T cells genetically modified with a tumour-reactive chimeric antigen receptor (CAR) is an innovative therapeutic concept, promising to eradicate cancer without causing secondary chronic diseases. This approach is already at an advanced stage of development in the US, but struggles in the EU, due to a number of constrains that will be specifically tackled by this Project. The ultimate goal of EURE-CART is to bring EU at the forefront CAR T-cell immunotherapy. In this Project, we will extend the applicability of CAR T-cell immunotherapy to incurable tumours that have never been tackled with this approach. The EURE-CART Consortium is composed of 6 academic centres, 2 SMEs and 1 large enterprise from 6 EU countries, clearly representing excellences in their respective fields. EURE-CART will bring together clinical experts in oncology, and pioneers and leaders in the field of cell and gene therapy for conducting a first-in-man Phase I/II clinical trial. To be successful, EURE-CART proposes the early involvement of National regulatory authorities for accelerating the approval of CAR T-cell immunotherapy, as well as the centralisation of its production by the Molmed Spa. Molmed Spa is uniquely endowed in the EU with the know-how and experience necessary to meet this ambitious objective, as demonstrated by its unparalleled track record. The main expected impact of EURE-CART is the establishment of CAR T-cell therapy as the ultimate personalised therapy, capable of defeating chronic diseases, and to create secure new jobs in the EU through the instalment of an unprecedented alliance between academia, industry and regulatory bodies.
Preparation of a project logo and flyer | Websites, patent fillings, videos etc. | 2019-05-31 16:44:17 |
Individualised press releases | Websites, patent fillings, videos etc. | 2019-05-31 17:41:12 |
Signing-up of dedicated Twitter and LinkedIn accounts | Websites, patent fillings, videos etc. | 2019-05-31 17:41:08 |
Launch of dedicated website | Websites, patent fillings, videos etc. | 2019-05-31 16:44:21 |
Take a look to the deliverables list in detail: detailed list of EURE-CART deliverables.
year | authors and title | journal | last update |
---|---|---|---|
2018 |
\"\"\"F. Moretti, F. Capone, C. Traversari, M.C. Galli\" Il Progetto europeo EURE-CART: l\'ISS tra i partner del nuovo approccio terapeutico e personalizzato per sconfiggere le malattie neoplastiche published pages: 3-5, ISSN: 1827-6296, DOI: |
Notiziario Istituto Superiore Sanità 31(11) | 2020-03-05 |
2018 |
Franco Locatelli, Concetta Quintarelli The EURE-CART project as a prototype model for CAR T-cell immunotherapy in Europe published pages: 216-219, ISSN: 0014-2980, DOI: 10.1002/eji.201870029 |
European Journal of Immunology 48/2 | 2019-06-11 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EURE-CART" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "EURE-CART" are provided by the European Opendata Portal: CORDIS opendata.